Laura Vaughan1,2, Darlene Veruttipong1,3, Jonathan G Shaw1,3, Noemie Levy4, Lauren Edwards1,2, Marcy Winget5,6. 1. Division of Primary Care & Population Health, Stanford University School of Medicine, 1265 Welch Rd., Mail Code 5475, Stanford, CA, 94305, USA. 2. Stanford Primary Care Los Altos, 960 N San Antonio Rd #101, Los Altos, CA, 94022, USA. 3. Evaluation Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, USA. 4. Stanford University School of Medicine, 291 Campus Drive, Stanford, CA, 94305, USA. 5. Division of Primary Care & Population Health, Stanford University School of Medicine, 1265 Welch Rd., Mail Code 5475, Stanford, CA, 94305, USA. mwinget@stanford.edu. 6. Evaluation Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, USA. mwinget@stanford.edu.
Abstract
BACKGROUND: COVID-19 studies are primarily from the inpatient setting, skewing towards severe disease. Race and comorbidities predict hospitalization, however, ambulatory presentation of milder COVID-19 disease and characteristics associated with progression to severe disease is not well-understood. METHODS: We conducted a retrospective chart review including all COVID-19 positive cases from Stanford Health Care (SHC) in March 2020 to assess demographics, comorbidities and symptoms in relationship to: 1) their access point of testing (outpatient, inpatient, and emergency room (ER)) and 2) development of severe disease. RESULTS: Two hundred fifty-seven patients tested positive: 127 (49%), 96 (37%), and 34 (13%) at outpatient, ER and inpatient, respectively. Overall, 61% were age < 55; age > 75 was rarer in outpatient setting (11%) than ER (14%) or inpatient (24%). Most patients presented with cough (86%), fever/chills (76%), or fatigue (63%). 65% of inpatients reported shortness of breath compared to 30-32% of outpatients and ER patients. Ethnic/minority patients had a significantly higher risk of developing severe disease (Asian OR = 4.8 [1.6-14.2], Hispanic OR = 3.6 [1.1-11.9]). Medicare-insured patients were marginally more likely (OR = 4.0 [0.9-17.8]). Other factors associated with developing severe disease included kidney disease (OR = 6.1 [1.0-38.1]), cardiovascular disease (OR = 4.7 [1.0-22.1], shortness of breath (OR = 5.4 [2.3-12.6]) and GI symptoms (OR = 3.3 [1.4-7.7]; hypertension without concomitant CVD or kidney disease was marginally significant (OR = 2.3 [0.8-6.5]). CONCLUSIONS: Early widespread symptomatic testing for COVID-19 in Silicon Valley included many less severely ill patients. Thorough manual review of symptomatology reconfirms the heterogeneity of COVID-19 symptoms, and challenges in using clinical characteristics to predict decline. We re-demonstrate that socio-demographics are consistently associated with severity.
BACKGROUND:COVID-19 studies are primarily from the inpatient setting, skewing towards severe disease. Race and comorbidities predict hospitalization, however, ambulatory presentation of milder COVID-19 disease and characteristics associated with progression to severe disease is not well-understood. METHODS: We conducted a retrospective chart review including all COVID-19 positive cases from Stanford Health Care (SHC) in March 2020 to assess demographics, comorbidities and symptoms in relationship to: 1) their access point of testing (outpatient, inpatient, and emergency room (ER)) and 2) development of severe disease. RESULTS: Two hundred fifty-seven patients tested positive: 127 (49%), 96 (37%), and 34 (13%) at outpatient, ER and inpatient, respectively. Overall, 61% were age < 55; age > 75 was rarer in outpatient setting (11%) than ER (14%) or inpatient (24%). Most patients presented with cough (86%), fever/chills (76%), or fatigue (63%). 65% of inpatients reported shortness of breath compared to 30-32% of outpatients and ERpatients. Ethnic/minority patients had a significantly higher risk of developing severe disease (Asian OR = 4.8 [1.6-14.2], Hispanic OR = 3.6 [1.1-11.9]). Medicare-insured patients were marginally more likely (OR = 4.0 [0.9-17.8]). Other factors associated with developing severe disease included kidney disease (OR = 6.1 [1.0-38.1]), cardiovascular disease (OR = 4.7 [1.0-22.1], shortness of breath (OR = 5.4 [2.3-12.6]) and GI symptoms (OR = 3.3 [1.4-7.7]; hypertension without concomitant CVD or kidney disease was marginally significant (OR = 2.3 [0.8-6.5]). CONCLUSIONS: Early widespread symptomatic testing for COVID-19 in Silicon Valley included many less severely ill patients. Thorough manual review of symptomatology reconfirms the heterogeneity of COVID-19 symptoms, and challenges in using clinical characteristics to predict decline. We re-demonstrate that socio-demographics are consistently associated with severity.
Authors: Amanda Ricciuto; Christopher A Lamb; Eric I Benchimol; Gareth J Walker; Nicholas A Kennedy; M Ellen Kuenzig; Gilaad G Kaplan; Michael D Kappelman; Ryan C Ungaro; Jean-Frederic Colombel; Erica J Brenner; Manasi Agrawal; Walter Reinisch; Anne M Griffiths; Shaji Sebastian Journal: J Crohns Colitis Date: 2022-05-10 Impact factor: 10.020
Authors: Matteo Bassetti; Daniele Roberto Giacobbe; Paolo Bruzzi; Emanuela Barisione; Stefano Centanni; Nadia Castaldo; Silvia Corcione; Francesco Giuseppe De Rosa; Fabiano Di Marco; Andrea Gori; Andrea Gramegna; Guido Granata; Angelo Gratarola; Alberto Enrico Maraolo; Malgorzata Mikulska; Andrea Lombardi; Federico Pea; Nicola Petrosillo; Dejan Radovanovic; Pierachille Santus; Alessio Signori; Emanuela Sozio; Elena Tagliabue; Carlo Tascini; Carlo Vancheri; Antonio Vena; Pierluigi Viale; Francesco Blasi Journal: Infect Dis Ther Date: 2021-07-30
Authors: Angela Lai; Megan L Chang; Ryan P O'Donnell; Changcheng Zhou; Jennifer A Sumner; Tzung K Hsiai Journal: Sci Total Environ Date: 2021-03-16 Impact factor: 7.963
Authors: Faryal Khamis; Salah Al Awaidy; Muna Al Shaaibi; Mubarak Al Shukeili; Shabnam Chhetri; Afra Al Balushi; Sumaiya Al Sulaimi; Amal Al Balushi; Ronald Wesonga Journal: Diseases Date: 2021-12-23
Authors: Vamsi P Guntur; Brian D Modena; Laurie A Manka; Jared J Eddy; Shu-Yi Liao; Nir M Goldstein; Pearlanne Zelarney; Carrie A Horn; Rebecca C Keith; Barry J Make; Irina Petrache; Michael E Wechsler Journal: Respir Med Date: 2022-04-07 Impact factor: 4.582
Authors: Ye Minn Htun; Tun Tun Win; Aung Aung; Thant Zin Latt; Yan Naung Phyo; Thet Min Tun; Nyan Sint Htun; Kyaw Myo Tun; Khin Aung Htun Journal: Trop Med Health Date: 2021-08-06
Authors: Gorka Lasso; Saad Khan; Stephanie A Allen; Margarette Mariano; Catalina Florez; Erika P Orner; Jose A Quiroz; Gregory Quevedo; Aldo Massimi; Aditi Hegde; Ariel S Wirchnianski; Robert H Bortz; Ryan J Malonis; George I Georgiev; Karen Tong; Natalia G Herrera; Nicholas C Morano; Scott J Garforth; Avinash Malaviya; Ahmed Khokhar; Ethan Laudermilch; M Eugenia Dieterle; J Maximilian Fels; Denise Haslwanter; Rohit K Jangra; Jason Barnhill; Steven C Almo; Kartik Chandran; Jonathan R Lai; Libusha Kelly; Johanna P Daily; Olivia Vergnolle Journal: PLoS Comput Biol Date: 2022-01-18 Impact factor: 4.475
Authors: Maja Artandi; Linda Barman; Malathi Srinivasan; Sam Thomas; Jaiveer Singh; Steven M Asch; Stacie Vilendrer Journal: Am J Med Qual Date: 2021-07-21 Impact factor: 1.200